Search

Your search keyword '"Louviaux I"' showing total 39 results
Start Over Author "Louviaux I"
39 results on '"Louviaux I"'

1. Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

Author

Geukens, T., Brandão, M., Laenen, A., Collignon, J., Van Marcke, C., Louviaux, I., Demey, W., Van Wambeke, S., Schrijvers, D., Lecomte, S., Mebis, J., Rutten, A., Fontaine, C., Lybaert, W., Aspeslagh, S., Goeminne, J.-C., Van Den Bulck, H., Seront, E., De Backer, L., De Roock, W., Ignatiadis, M., Prenen, H., Van Beckhoven, D., Heijlen, M., Verheezen, J., Rottey, S., Punie, K., and de Azambuja, E.

Published
2022
Full Text
View/download PDF

2. Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Geukens, T, Brandão, M, Laenen, A, Collignon, J, Van Marcke, C, Louviaux, I, Demey, W, Van Wambeke, S, Schrijvers, D, Lecomte, S, Mebis, J, Rutten, A, Fontaine, C, Lybaert, W, Aspeslagh, S, Goeminne, Jean-Charles, Van Den Bulck, H, Seront, E, De Backer, L, De Roock, W, Ignatiadis, M, Prenen, H, Van Beckhoven, D, Heijlen, M, Verheezen, J, Rottey, S, Punie, K, de Azambuja, E, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Geukens, T, Brandão, M, Laenen, A, Collignon, J, Van Marcke, C, Louviaux, I, Demey, W, Van Wambeke, S, Schrijvers, D, Lecomte, S, Mebis, J, Rutten, A, Fontaine, C, Lybaert, W, Aspeslagh, S, Goeminne, Jean-Charles, Van Den Bulck, H, Seront, E, De Backer, L, De Roock, W, Ignatiadis, M, Prenen, H, Van Beckhoven, D, Heijlen, M, Verheezen, J, Rottey, S, Punie, K, and de Azambuja, E

Abstract

Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first analyses of a nationwide database of patients with cancer hospitalized with COVID-19 in Belgium, with a focus on changes in anticancer treatment plans at the time of SARS-CoV-2 infection. Nineteen Belgian hospitals identified all patients with a history of solid cancer hospitalized with COVID-19 between March 2020 and February 2021. Demographic, cancer-specific and COVID-specific data were pseudonymously entered into a central Belgian Society of Medical Oncology (BSMO)-COVID database. The association between survival and primary cancer type was analyzed through multivariate multinomial logistic regression. Group comparisons for categorical variables were carried out through a Chi-square test. A total of 928 patients were registered in the database; most of them were aged ≥70 years (61.0%) and with poor performance scores [57.2% Eastern Cooperative Oncology Group (ECOG) ≥2]. Thirty-day COVID-related mortality was 19.8%. In multivariate analysis, a trend was seen for higher mortality in patients with lung cancer (27.6% versus 20.8%, P = 0.062) and lower mortality for patients with breast cancer (13.0% versus 23.3%, P = 0.052) compared with other tumour types. Non-curative treatment was associated with higher 30-day COVID-related mortality rates compared with curative or no active treatment (25.8% versus 14.3% versus 21.9%, respectively, P < 0.001). In 33% of patients under active treatment, the therapeutic plan was changed due to COVID-19 diagnosis, most frequently involving delays/interruptions in systemic treatments (18.6%). Thirty-day COVID-related mortality was not significantly different between patients with and without treatment modifications (21.4% versus 20.5%). Interruption in anticancer treatments at the time of SARS-CoV-2 infection was not associated with a reduction

Published
2022

9. Surrogate markers predicting overall survival for lung cancer : elcwp recommendations

Author

Berghmans , T., Pasleau , F., Paesmans , M., Bonduelle , Y., Cadranel , J., Cs Toth , I., Garcia , C., Giner , V., Holbrechts , S., Lafitte , J. J., Lecomte , J., Louviaux , I., Markiewicz , E., Meert , A. P., Richez , M., Roelandts , M., Scherpereel , A., Tulippe , Ch, Van Houtte , P., Van Schil , P., Wachters , C., Westeel , V., Sculier , J. P., Renseigné , Non, Museu Nacl Hist Nat, Université de Lisbonne, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Oncology, Lung Neoplasms, medicine.medical_treatment, Medical Oncology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, MESH : Tumor Markers, Biological, Pulmonary Medicine, 030212 general & internal medicine, MESH: Treatment Outcome, MESH: Medical Oncology, MESH : Evidence-Based Medicine, Evidence-Based Medicine, Respiratory disease, MESH: Guidelines as Topic, 3. Good health, Europe, Treatment Outcome, 030220 oncology & carcinogenesis, MESH : Disease-Free Survival, Pulmonary and Respiratory Medicine, medicine.medical_specialty, MESH : Europe, MEDLINE, Guidelines as Topic, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Disease-Free Survival, 03 medical and health sciences, MESH : Medical Oncology, Internal medicine, Biomarkers, Tumor, medicine, Carcinoma, Overall survival, Humans, MESH : Lung Neoplasms, Lung cancer, MESH: Pulmonary Medicine, MESH : Guidelines as Topic, MESH : Pulmonary Medicine, MESH: Humans, MESH : Carcinoma, Non-Small-Cell Lung, business.industry, MESH : Humans, MESH: Biological Markers, Cancer, Evidence-based medicine, medicine.disease, Surgery, MESH: Lung Neoplasms, respiratory tract diseases, Radiation therapy, MESH : Biological Markers, MESH: Tumor Markers, Biological, MESH: Disease-Free Survival, MESH: Europe, Human medicine, business, Biomarkers, MESH: Carcinoma, Non-Small-Cell Lung, MESH: Evidence-Based Medicine
Abstract

International audience; The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.

Published
2011
Full Text
View/download PDF

10. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

Author

Berghmans, Thierry, Pasleau, Françoise, Paesmans, Marianne, Bonduelle, Yves, Cadranel, Jacques, Toth, Cory, Garcia, Camilo, Giner, Vicente, Holbrechts, Stéphane, Lafitte, Jean-Jacques, Lecomte, J., Louviaux, I., Markiewicz, Eveline, Meert, Anne-Pascale, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Tulippe, Christian, Van Houtte, Paul, Van Schil, Paul, Wachters, Claire, Westeel, Virginie, Sculier, Jean-Paul, Berghmans, Thierry, Pasleau, Françoise, Paesmans, Marianne, Bonduelle, Yves, Cadranel, Jacques, Toth, Cory, Garcia, Camilo, Giner, Vicente, Holbrechts, Stéphane, Lafitte, Jean-Jacques, Lecomte, J., Louviaux, I., Markiewicz, Eveline, Meert, Anne-Pascale, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Tulippe, Christian, Van Houtte, Paul, Van Schil, Paul, Wachters, Claire, Westeel, Virginie, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/published

Published
2012

11. Traitement du cancer bronchique à petites cellules: Maladies étendues. Les recommandations de pratique clinique de l'European Lung Cancer Working Party

Author

Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Collon, Thierry, Dusart, Michelle, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Leclercq, Nathalie, Lecomte, J., Louviaux, I., Markiewicz, Eveline, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Sculier, Jean-Paul, Van Houtte, Paul, Wackenier, Peggy, Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Collon, Thierry, Dusart, Michelle, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Leclercq, Nathalie, Lecomte, J., Louviaux, I., Markiewicz, Eveline, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Sculier, Jean-Paul, Van Houtte, Paul, and Wackenier, Peggy

Abstract

SCOPUS: re.j, info:eu-repo/semantics/published

Published
2008

12. Traitement du cancer bronchique à petites cellules: Maladies limitées. Les recommandations de pratique clinique de l'European Lung Cancer Working Party

Author

Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Sculier, Jean-Paul, Van Houtte, Paul, Wackenier, Peggy, Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Sculier, Jean-Paul, Van Houtte, Paul, and Wackenier, Peggy

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2008

13. European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: IV. Limited disease.

Author

Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Sculier, Jean-Paul, Van Houtte, Paul, Wackenier, Peggy, Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Sculier, Jean-Paul, Van Houtte, Paul, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2007

14. European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: V. Extensive diseases.

Author

Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Collon, Thierry, Dusart, Michelle, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Leclercq, Nathalie, Lecomte, J., Louviaux, I., Markiewicz, Eveline, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Sculier, Jean-Paul, Van Houtte, Paul, Wackenier, Peggy, Alexopoulos, Constantinos, Berchier, M.C., Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Collon, Thierry, Dusart, Michelle, Ficheroulle, X., Giner, Vicente, Kotsori, Katerina, Lafitte, Jean-Jacques, Leclercq, Nathalie, Lecomte, J., Louviaux, I., Markiewicz, Eveline, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Sculier, Jean-Paul, Van Houtte, Paul, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2007

15. Traitement des cancers bronchiques non à petites cellules: Maladies avancées (métastatiques). Les recommandations de pratique clinique de l'European Lung Cancer Working Party

Author

Alard, Serge, Alexopoulos, Constantinos, Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Collon, Thierry, Efremidis, Anna, Ficheroulle, X., Florin, M.C., Giner, Vicente, Holbrechts, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Leclercq, Nathalie, Louviaux, I., Markiewicz, Eveline, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Sculier, Jean-Paul, Van Houtte, Paul, Vaslamatzis, Michael, Wackenier, Peggy, Alard, Serge, Alexopoulos, Constantinos, Berghmans, Thierry, Bonduelle, Y., Colinet, Benoît, Collon, Thierry, Efremidis, Anna, Ficheroulle, X., Florin, M.C., Giner, Vicente, Holbrechts, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Leclercq, Nathalie, Louviaux, I., Markiewicz, Eveline, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Roelandts, Martine, Sculier, Jean-Paul, Van Houtte, Paul, Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

SCOPUS: re.j, info:eu-repo/semantics/published

Published
2007

16. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: I. Early stages.

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2006

17. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: III. Metastatic disease.

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2006

18. Traitement des cancers bronchiques non à petites cellules et résécables. Recommandations de pratique clinique de l'European Lung Cancer Working Party

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2006

19. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: II. Unresectable non-metastatic stages.

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2006

20. Chemotherapy for malignant mesothelioma: a quantitative and qualitative overview of the literature.

Author

Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Berghmans, Thierry, Paesmans, Marianne, Lalami, Yassine, Louviaux, I., Luce, Sylvie, Mascaux, Céline, Meert, Anne-Pascale, Sculier, Jean-Paul, Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Berghmans, Thierry, Paesmans, Marianne, Lalami, Yassine, Louviaux, I., Luce, Sylvie, Mascaux, Céline, Meert, Anne-Pascale, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

Published
2002

21. Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis

Author

Berghmans, Thierry, Paesmans, Marianne, Lalami, Yassine, Louviaux, I., Luce, Sylvie, Mascaux, Céline, Meert, Anne-Pascale, Sculier, Jean-Paul, Berghmans, Thierry, Paesmans, Marianne, Lalami, Yassine, Louviaux, I., Luce, Sylvie, Mascaux, Céline, Meert, Anne-Pascale, and Sculier, Jean-Paul

Abstract

The role of chemotherapy for unresectable malignant mesothelioma is unclear. The aims of the present study were to evaluate the methodological quality of published papers relative to chemotherapy or immunotherapy in malignant mesothelioma and to aggregate, for trials having a similar methodology, the response rates in order to identify the most active chemotherapeutic drugs and regimens. The literature relative to this topic, published between 1965 and June 2001 was reviewed. A methodological qualitative evaluation was performed according to the European Lung Cancer Working Party scale, specifically designed for phase II trials. A study was considered as potentially positive if the upper limit of the 95% confidence interval (CI) of the response rate was greater than 20% and positive if the lower limit of the 95% CI was >20%. Eighty-three studies (88 treatment arms) were eligible for the systematic review. Fifty-three arms were considered as positive or potentially positive. No statistically significant difference in the methodological quality was observed between negative and positive studies. Studies were aggregated in four groups according to the presence of cisplatin and/or doxorubicin in the treatment regimen. The combination of cisplatin and doxorubicin had the highest response rate (28.5%; P<0.001). Cisplatin was the most active single-agent regimen. Our systematic qualitative and quantitative overview of the literature suggests that the most active chemotherapeutic regimen, in term of objective response rate, is the combination of cisplatin and doxorubicin and the best single-agent is cisplatin. The combination of these two drugs can be recommended as control arm for future randomised phase III trials. Copyright © 2002 Elsevier Science Ireland Ltd., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2002

22. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

Author

UCL - MD/MINT - Département de médecine interne, UCL - MD/RAIM - Département de radiologie et d'imagerie médicale, UCL - (SLuc) Service de radiologie, Van Den Neste, Eric, Doyen, Chantal, Louviaux, I, Michaux, Jean-Louis, Delannoy, André, Michaux, Lucienne, Sonet, Anne, Bosly, André, Mineur, P., André, Marc, Straetmans, Nicole, Coche, Edgard, Venet, C, Duprez, Thierry, Ferrant, Augustin, UCL - MD/MINT - Département de médecine interne, UCL - MD/RAIM - Département de radiologie et d'imagerie médicale, UCL - (SLuc) Service de radiologie, Van Den Neste, Eric, Doyen, Chantal, Louviaux, I, Michaux, Jean-Louis, Delannoy, André, Michaux, Lucienne, Sonet, Anne, Bosly, André, Mineur, P., André, Marc, Straetmans, Nicole, Coche, Edgard, Venet, C, Duprez, Thierry, and Ferrant, Augustin

Abstract

Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) infusion, immediately followed by a 1-h i.v. infusion of CP, for 3 days. The initial daily CP dose was 200 mg/m2, and was escalated by 100 mg/m2 increments in successive cohorts of three to six patients to determine the maximum-tolerated dose (MTD). Additional patients were included at the MTD to extend toxicity and response analysis. Twenty-six patients received 68 cycles of chemotherapy. The MTD of CP after CdA 5.6 mg/m2, was 300 mg/m2. Acute neutropenia was the dose-limiting toxicity of this regimen, which was otherwise well tolerated. Delivery of repeated cycles was not feasible in eight patients (31%) because of prolonged thrombocytopenia. Severe infections were seen in three of 68 cycles (4%). The overall response rate was 58% (15 of 26; 95% CI, 36-76%), with 15% complete responses and 42% partial responses. These data show the feasibility of the association of CdA with CP. Given the response rate observed, further studies of this regimen are warranted in untreated patients, in particular with chronic lymphocytic leukemia and with Waldenström macroglobulinemia.

Published
2000

24. Digital clubbing in a patient with progressive mantle cell lymphoma.

Author

UCL - MD/MNOP - Département de morphologie normale et pathologique, UCL - MD/MINT - Département de médecine interne, Louviaux, I, Van Den Neste, Eric, Scheiff, Jean-Marie, Michaux, Lucienne, Straetmans, Nicole, Ferrant, Augustin, UCL - MD/MNOP - Département de morphologie normale et pathologique, UCL - MD/MINT - Département de médecine interne, Louviaux, I, Van Den Neste, Eric, Scheiff, Jean-Marie, Michaux, Lucienne, Straetmans, Nicole, and Ferrant, Augustin

Abstract

Digital clubbing with or without hypertrophic osteoarthropathy may occur in a variety of neoplastic diseases. We present the first description of digital clubbing in a patient with progressive mantle cell lymphoma, in the absence of any other apparent etiology. We suggest that clubbing might be a paraneoplastic manifestation in mantle cell lymphoma. The literature on digital clubbing in hematological neoplasms is reviewed.

Published
1999

25. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/BICL - Département de biochimie et de biologie cellulaire, UCL - MD/MNOP - Département de morphologie normale et pathologique, UCL - MD/MINT - Département de médecine interne, Van Den Neste, Eric, Scheiff, Jean-Marie, Bontemps, Françoise, Delacauw, A, Cardoen, S, Louviaux, I, Gillis, E, Leveugle, P, Deneys, Véronique, Ferrant, Augustin, Van den Berghe, Georges, UCL - Cliniques universitaires Saint-Luc, UCL - MD/BICL - Département de biochimie et de biologie cellulaire, UCL - MD/MNOP - Département de morphologie normale et pathologique, UCL - MD/MINT - Département de médecine interne, Van Den Neste, Eric, Scheiff, Jean-Marie, Bontemps, Françoise, Delacauw, A, Cardoen, S, Louviaux, I, Gillis, E, Leveugle, P, Deneys, Véronique, Ferrant, Augustin, and Van den Berghe, Georges

Abstract

Because 2-chloro-2'-deoxyadenosine (CdA) is active in B-chronic lymphocytic leukemia (B-CLL), and may interfere with DNA repair, we investigated the potentiating effect of CdA on the cytotoxicity induced in vitro in B-CLL lymphocytes by cyclophosphamide (CP) derivatives, which induce DNA damage by DNA cross-linking. Exposure to CdA at clinically achievable concentrations for 2 h, followed by mafosfamide (MAF) or 4-hydroxycyclophosphamide (4HC) for 22 h, resulted in synergistic cytotoxicity in the majority of B-CLL samples tested. Synergy between CdA and MAF was observed in cell samples of sensitive/untreated patients, as well as in cells of resistant/pretreated patients, particularly at the highest concentrations of MAF. In the cells treated with CdA and MAF, we observed loss in ATP and hallmarks of apoptosis, as evidenced by cellular morphology and high molecular weight DNA fragmentation. The synergy could be explained neither by an influence of MAF on the phosphorylation of CdA, nor by an increase in the incorporation of CdA into DNA in the presence of MAF. The in vitro synergy between CdA and CP derivatives provides a rationale for the use of this association in B-CLL patients.

Published
1999

26. Chemotherapy for malignant mesothelioma: a quantitative and qualitative overview of the literature

Author

Berghmans, Thierry, Paesmans, Marianne, Lalami, Yassine, Lemaitre, France, Louviaux, I., Luce, Sylvie, Pegrimcova, R., Vermylen, Philippe, Sculier, Jean-Paul, Berghmans, Thierry, Paesmans, Marianne, Lalami, Yassine, Lemaitre, France, Louviaux, I., Luce, Sylvie, Pegrimcova, R., Vermylen, Philippe, and Sculier, Jean-Paul

Abstract

35th ASCO, May 15-18, 1999, info:eu-repo/semantics/published

Published
1999

28. Cytogenetic abnormalities in Waldenstrom's disease (WD): A single centre study on 45 cases.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Louviaux, I, Michaux, Lucienne, Ferrant, Augustin, Hagemeijer, Anne, Criel, A., Billiet, J, Scheiff, Jean-Marie, Deneys, Véronique, Delannoy, L, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Louviaux, I, Michaux, Lucienne, Ferrant, Augustin, Hagemeijer, Anne, Criel, A., Billiet, J, Scheiff, Jean-Marie, Deneys, Véronique, and Delannoy, L

Published
1998

29. Phase I/II study of 2-chloro-2 '-deoxyadenosine (CdA) in combination with cyclophosphamide (CP) in patients (pts) with advanced low grade lymphoid malignancies.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Van Den Neste, Eric, Michaux, Lucienne, Ferrant, Augustin, Louviaux, I, Delannoy, André, Michaux, JL., Bosly, André, Sonet, Anne, Doyen, Chantal, Meyns, M, André, Marc, Mineur, P., Straetmans, Nicole, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Van Den Neste, Eric, Michaux, Lucienne, Ferrant, Augustin, Louviaux, I, Delannoy, André, Michaux, JL., Bosly, André, Sonet, Anne, Doyen, Chantal, Meyns, M, André, Marc, Mineur, P., and Straetmans, Nicole

Published
1998

34. [Medulloblastoma : management of a usually pediatric tumour in a young adult].

Author

Chatelain C, Piette C, Bex A, Bex V, Janin N, Salmon JP, Cabay JE, El Hachemi M, Jaspers A, Ben Mustapha S, and Louviaux I

Subjects
Adult, Child, Humans, Male, Young Adult, Cerebellar Neoplasms drug therapy, Cerebellar Neoplasms pathology, Cerebellar Neoplasms surgery, Medulloblastoma drug therapy, Medulloblastoma therapy
Abstract

Medulloblastoma is a cerebellar grade IV tumour according to the WHO classification, mainly seen in children under the age of 15. This cancer can nevertheless occur in adults. We report the case of a 22-year-old patient with a medulloblastoma disseminated in the spine. The patient had a type 1 Arnold-Chiari malformation causing hydrocephalus treated by ventriculoperitoneal shunt. The current condition began with perineal and lower limb hypoesthesia, ataxic gait, erectile dysfunction and urinary incontinence. Subsequently, a predominant paraparesis of the right lower limb appeared. The patient was treated according to the PNET HR+5 protocol combining two courses of conventional chemotherapy followed by two courses of high-dose chemotherapy with autograft recovery. Given the excellent response, a proton therapy was then delivered to the whole cerebrospinal axis with boosts to the primary tumour sites. The case of this young adult patient shows on the one hand an atypical presentation, and on the other hand underlines, in the absence of a specific therapeutic strategy established for adults, the importance of collaboration between the adult and pediatric oncology departments, with management integrating innovations such as proton therapy and molecular typing.

Published
2022

35. [Multiple myeloma in an elderly patient with history of breast cancer : the value of multidisciplinary oncogeriatric collaboration].

Author

Legros M, Bouillon AS, Janin N, Moonen M, Louviaux I, Salmon JP, Berg N, and Servais P

Subjects
Aged, Geriatric Assessment, Humans, Quality of Life, Breast Neoplasms complications, Breast Neoplasms therapy, Frailty, Multiple Myeloma complications, Multiple Myeloma diagnosis, Multiple Myeloma therapy
Abstract

As the prevalence of cancers increases with age, some elderly patients are confronted with multiple tumoural pathologies. The clinical case of a 70-year-old patient with adenocarcinoma of the breast and multiple myeloma complicated by severe renal failure illustrates the complexity of oncogeriatric management. The geriatric assessment makes it possible to detect frailty and provides assistance in the development of a personalized care plan while respecting the quality of life.

Published
2021

36. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

Author

de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, Collignon J, Lybaert W, Verheezen J, Rutten A, Vuylsteke P, Goeminne JC, Demey W, Van Beckhoven D, Deblonde J, Rottey S, Geukens T, Punie K, Bafort K, Belkhir L, Bossuyt N, Colombie V, Daubresse C, Dauby N, De Munter P, Delmarcelle D, Delvallee M, Demeester R, Delefortrie Q, Dugernier T, Holemans X, Louviaux I, Machurot P, Minette P, Mokrane S, Nachtergal C, Noirhomme S, Piérard D, Rossi C, Schirvel C, Sermijn E, Staelens F, Triest F, Van Beckhoven D, Van Goethem N, Van Praet J, Vanhoenacker A, Verstraete R, Willems E, and Wyndham-Thomas C

Subjects
Adrenal Cortex Hormones therapeutic use, Aged, Aged, 80 and over, Belgium epidemiology, COVID-19, Comorbidity, Coronavirus Infections diagnostic imaging, Coronavirus Infections virology, Female, Hospitalization, Humans, Intensive Care Units, Lung diagnostic imaging, Male, Middle Aged, Neoplasms drug therapy, Pandemics, Pneumonia, Viral diagnostic imaging, Pneumonia, Viral virology, Prognosis, Respiration, Artificial, Risk Factors, SARS-CoV-2, Betacoronavirus, Coronavirus Infections epidemiology, Coronavirus Infections mortality, Hospital Mortality, Neoplasms epidemiology, Pneumonia, Viral epidemiology, Pneumonia, Viral mortality
Abstract

Background: Cancer seems to have an independent adverse prognostic effect on COVID-19-related mortality, but uncertainty exists regarding its effect across different patient subgroups. We report a population-based analysis of patients hospitalised with COVID-19 with prior or current solid cancer versus those without cancer., Methods: We analysed data of adult patients registered until 24 May 2020 in the Belgian nationwide database of Sciensano. The primary objective was in-hospital mortality within 30 days of COVID-19 diagnosis among patients with solid cancer versus patients without cancer. Severe event occurrence, a composite of intensive care unit admission, invasive ventilation and/or death, was a secondary objective. These endpoints were analysed across different patient subgroups. Multivariable logistic regression models were used to analyse the association between cancer and clinical characteristics (baseline analysis) and the effect of cancer on in-hospital mortality and on severe event occurrence, adjusting for clinical characteristics (in-hospital analysis)., Results: A total of 13 594 patients (of whom 1187 with solid cancer (8.7%)) were evaluable for the baseline analysis and 10 486 (892 with solid cancer (8.5%)) for the in-hospital analysis. Patients with cancer were older and presented with less symptoms/signs and lung imaging alterations. The 30-day in-hospital mortality was higher in patients with solid cancer compared with patients without cancer (31.7% vs 20.0%, respectively; adjusted OR (aOR) 1.34; 95% CI 1.13 to 1.58). The aOR was 3.84 (95% CI 1.94 to 7.59) among younger patients (<60 years) and 2.27 (95% CI 1.41 to 3.64) among patients without other comorbidities. Severe event occurrence was similar in both groups (36.7% vs 28.8%; aOR 1.10; 95% CI 0.95 to 1.29)., Conclusions: This population-based analysis demonstrates that solid cancer is an independent adverse prognostic factor for in-hospital mortality among patients with COVID-19. This adverse effect was more pronounced among younger patients and those without other comorbidities. Patients with solid cancer should be prioritised in vaccination campaigns and in tailored containment measurements., Competing Interests: Competing interests: EdA: honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen and Zodiac; travel grants from Roche/GNE and GSK/Novartis; research grants to his institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. MB: speaker honoraria and travel grants from Roche/GNE; research grants to her institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. HW: his institution received consulting fees and honoraria from AstraZeneca, Biocartis, Lilly, Novartis, Pfizer, PUMA Biotechnology, Roche, Sirtex, Daiichi; his institution received unrestricted research grants from Roche and Novartis; he received travel support from Roche and Pfizer. AL: no conflicts of interest to disclose. SA: speaker fees from BMS, AstraZeneca, Roche, Sanofi and Novartis; travel grants from Pfizer, Roche; advisory board fee from Sanofi and Pierre Fabre. CF: advisory board fee from Lilly. JC: advisory board and lectures from Amgen, Servier, Bayer, Novartis, Pfizer, Celgen, Ipsen (paid to institution); travel grants from Roche, Pfizer, Amgen, Novartis. WL: honoraria and/or advisory board from BMS, MSD, Novartis, IPSEN and Bayer; travel support from Roche, MSD and IPSEN. JV: no conflicts of interest to disclose. AR: honoraria and/or advisory board from Sanofi, BMS, Novartis, Pierre Fabre, Roche; travel support from Roche, BMS, MSD. PV: honoraria and/or advisory board from Roche, Novartis, Pfizer, Lilly, MSD, Merus; travel grants from Roche, AstraZeneca, MSD and Pfizer; speaker fees from Pfizer and Roche (paid to institution). JCG: advisory board and lectures from Ipsen, BMS, Janssen, Bayer, AstraZeneca. WD: honoraria and/or advisory board from Amgen, Pierre Fabre. DVB: no conflicts of interest to disclose JD: no conflicts of interest to disclose. SR: consulting fees and honoraria from J&J, Roche, Pfizer, AstraZeneca, Novartis, Bayer, MSD, BMS, Ipsen; research grants from Roche, BSM and MSD; travel grants from Ipsen, Pfizer, Bayer. TG: no conflicts of interest to disclose. KP: honoraria for advisory/consultancy roles for AstraZeneca, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Hoffmann/La Roche and Vifor Pharma (paid to institution); speaker fees for Eli Lilly, Mundi Pharma, Novartis, Pfizer and Hoffmann/La Roche (paid to institution); research funding from Sanofi (paid to institution); travel support from AstraZeneca, Novartis, Pfizer, PharmaMar and Hoffmann/La Roche., (© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)

Published
2020
Full Text
View/download PDF

37. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.

Author

Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D, Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, and Rottey S

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Female, Head and Neck Neoplasms mortality, Humans, Male, Methotrexate adverse effects, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local mortality, Squamous Cell Carcinoma of Head and Neck, Taxoids adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy, Methotrexate therapeutic use, Neoplasm Recurrence, Local drug therapy, Taxoids therapeutic use
Abstract

Lessons Learned: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%)., Background: Cabazitaxel is a second-generation taxane that improves the survival of patients with metastatic castrate-resistant prostate cancer following docetaxel therapy. Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. In this randomized phase II trial, we investigated cabazitaxel in patients with recurrent SCCHN., Methods: Patients with incurable SCCHN with progression after platinum-based therapy were randomly assigned to cabazitaxel every 3 weeks (cycle 1, 20 mg/m 2 , increased to 25 mg/m 2 for subsequent cycles in the absence of nonhematological adverse events [AEs] greater than grade 2 and hematological AEs greater than grade 3) or methotrexate (40 mg/m 2 /week). The patients were stratified according to their performance status and previous platinum-based chemotherapy for palliation versus curative intent. The primary endpoint was the progression-free survival rate (PFSR) at 18 weeks., Results: Of the 101 patients, 53 and 48, with a median age of 58.0 years (range, 41-80), were randomly assigned to cabazitaxel or methotrexate, respectively. The PFSR at 18 weeks was 13.2% (95% confidence interval [CI], 5%-25%) for cabazitaxel and 8.3% (95% CI, 2%-20%) for methotrexate. The median progression-free survival was 1.9 months in both arms. The median overall survival was 5.0 and 3.6 months for cabazitaxel and methotrexate, respectively. More patients experienced serious adverse events with cabazitaxel than with methotrexate (54% vs. 36%). The most common drug-related grade 3-4 AE in the cabazitaxel arm was febrile neutropenia (17.3%)., Conclusion: This study did not meet its primary endpoint. Cabazitaxel has low activity in recurrent SCCHN., Competing Interests: of potential conflicts of interest may be found at the end of this article., (©AlphaMed Press; the data published online to support this summary is the property of the authors.)

Published
2016
Full Text
View/download PDF

38. [Clinical case of the month. The role of radiotherapy for the treatment of advanced squamous cell carcinoma of the vulva. Case report and review of the literature].

Author

Werenne X, Hermesse J, Coucke P, Louviaux I, and Goffin F

Subjects
Adult, Carcinoma, Squamous Cell pathology, Female, Humans, Vulvar Neoplasms pathology, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Vulvar Neoplasms therapy
Abstract

Locally advanced squamous cell carcinoma of the vulva is treated with concomitant chemoradiotherapy if surgery is too mutilating and/or implies the use of stomy. We report in this paper, the unusual case of a young patient treated successfully with this non-surgical approach.

Published
2013

39. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations.

Author

Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, Garcia C, Giner V, Holbrechts S, Lafitte JJ, Lecomte J, Louviaux I, Markiewicz E, Meert AP, Richez M, Roelandts M, Scherpereel A, Tulippe Ch, Van Houtte P, Van Schil P, Wachters C, Westeel V, and Sculier JP

Subjects
Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Non-Small-Cell Lung therapy, Disease-Free Survival, Europe, Evidence-Based Medicine, Guidelines as Topic, Humans, Lung Neoplasms surgery, Lung Neoplasms therapy, Medical Oncology methods, Treatment Outcome, Biomarkers metabolism, Biomarkers, Tumor metabolism, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung diagnosis, Lung Neoplasms blood, Lung Neoplasms diagnosis, Medical Oncology standards, Pulmonary Medicine methods
Abstract

The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results